Literature DB >> 16423589

Lessons from Kawasaki disease: all brands of IVIG are not equal.

E Richard Stiehm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16423589     DOI： 10.1016/j.jpeds.2005.09.019

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  4 in total

1.  Identification of Differentially Expressed Genes in Kawasaki Disease Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics Analysis.

Authors:  Lan He; Youyu Sheng; Chunyun Huang; Guoying Huang
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

Review 2.  Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.

Authors:  Ming-Chih Lin
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

3.  Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study.

Authors:  Ming-Chih Lin; Yun-Ching Fu; Sheng-Ling Jan; Mei-Shu Lai
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

4.  Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose "IVIG-SN" Therapy for Pediatric Patients with Kawasaki Disease.

Authors:  Kyung Lim Yoon; Hae Yong Lee; Jeong Jin Yu; Jae Young Lee; Mi Young Han; Ki Yong Kim; June Huh
Journal:  Korean Circ J       Date:  2017-03-10       Impact factor: 3.243
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.